乙型肝炎病毒感染率在多发性骨髓瘤及健康体检人群的病例对照研究

王立茹; 陈以娟; 李星; 郭天娇; 李茜; 路瑾; 黄晓军

doi:10.3969/j.issn.1000-8179.20140926

乙型肝炎病毒感染率在多发性骨髓瘤及健康体检人群的病例对照研究

doi: 10.3969/j.issn.1000-8179.20140926

王立茹^①,,
陈以娟^①,
李星^①,
郭天娇^①,
李茜^①,
路瑾^②, ,,
黄晓军^②

①.
首都医科大学附属复兴医院（北京市100038）
②.
北京大学人民医院，北京大学血液病研究所

基金项目:

国家自然科学基金面上项目 81372535

北京大学创新药物研究开发技术平台建设项目 2012ZX09303019

详细信息

作者简介:
王立茹主任医师，副教授，硕士研究生导师。研究方向为血液病免疫治疗、造血干细胞移植后病毒感染合并症。E-mail：wanglirumail@126.com

通讯作者:
路瑾 jin1lu@sina.com

计量
- 文章访问数: 87
- HTML全文浏览量: 35
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-08
- 修回日期: 2014-05-20
- 刊出日期: 2014-07-15

A case-control study of hepatitis B virus infection in multiple myeloma patients and healthy controls

WANG Liru^{①
,},
CHEN Yijuan^①,
LI Xing^①,
GUO Tianjiao^①,
LI Qian^①,
LU Jin^{②
, ,},
HUANG Xiaojun^②

①.
Hematology Department, Fu-xing Hospital, Capital Medical University, Beijing 100038
②.
2 Peking University Institute of Hematology, Peking University People's Hospital, Beijing 100044, China

Funds:

the National Natural Science Foundation of China 81372535

the Construction of Innovative Drug Research and Development Platform 2012ZX09303019

More Information

Corresponding author: Jin LU; E-mail: jin1lu@sina.com

摘要

摘要: 目的比较乙型肝炎病毒（HBV）在多发性骨髓瘤（MM）患者中的感染率有无增加，及合并HBV感染MM患者的临床特征。方法以363例MM患者为研究对象，同时期11 227例健康体检者为对照组。采用免疫发光法检测HBV血清学标志物，实时定量聚合酶链反应检测HBV-DNA。比较HBsAg阳性和HBsAg阴性MM患者的临床特征及OS。结果化疗前16例（4.4%）MM患者HBsAg阳性，高于同期健康体检者（2.4%，P=0.015）。HBsAg阳性与HBsAg阴性MM患者相比，两组MM患者的总生存期无显著差别。2例接受含硼替佐米和地塞米松方案治疗的HBsAg阳性患者化疗后出现肝功异常和HBV再激活，应用抗乙肝药物可以抑制其HBV复制。结论 MM患者具有较体检人群高的HBV感染率，在治疗过程中需要密切监测HBsAg阳性患者的HBV复制并予以抗乙肝治疗。
- 多发性骨髓瘤 /
- 乙型肝炎病毒 /
- 化疗 /
- 再激活 /
- 硼替佐米
Abstract: Objective To explore the prevalence of hepatitis B virus (HBV) in multiple myeloma (MM) patients, as well as to compare the clinical characteristics and outcome between HBV infected and non-HBV infected patients. Methods The serology markers of HBV were detected in 363 MM patients and 11227 cases of healthy controls through chemiluminescence. HBV-DNA was measured via real-time quantitative chain reaction. Results Sixteen out of 363 MM patients (4.4%) were HBsAg-positive, showing significant difference with healthy controls (2.4%). No statistically significant differences were observed in terms of sex, age, type of monoclonal (M) protein, International Staging System (ISS) stage, stem cell transplantation, and risk stratification between HBsAg-positive and HBsAg-negative patients. No significant effect of HBV infection was found on the OS of MM patients. HBV reactivation was observed in two HBsAg-positive MM patients who were treated with combination chemotherapy, including bortezomib and dexamethasone. The replication of HBV could be inhibited by anti-HBV drugs. Conclusion A higher prevalence of HBV infection was revealed in MM patients. Close monitoring of HBV replication should be conducted in MM patients with HBV infection before and during the courses of chemotherapy.
- multiple myeloma /
- hepatitis B virus /
- chemotherapy /
- reactivation /
- bortezomib

HTML全文

图 1 比较HBsAg阳性和HBsAg阴性患者的总生存率

Figure 1. Comparison of overall survival between HBsAg positive and HBsAg negtive patients

下载: 全尺寸图片幻灯片

表 1 健康体检者与多发性骨髓瘤患者HBV血清学特征

Table 1. Characteristics of HBV infection in multiple myeloma patients and healthy controls

表 2 比较HBsAg阳性与HBsAg阴性MM患者的临床特征 n（%）

Table 2. Comparison of clinical characteristics between HBsAg-positive and HBsAg-negative multiple myeloma patients

参考文献(19)

[1]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases. The guideline of prevention and treatment for chronic hepatitis B (2010 version)[J]. Chin J Hepatol, 2011, 19(1):13-24. http://cn.bing.com/academic/profile?id=ca7507cffd0854ac644d812503c13183&encoded=0&v=paper_preview&mkt=zh-cn
[2]	Schiller JT, Lowy DR. Virus infection and human cancer: an overview[J]. Recent Results Cancer Res, 2014, 193:1-10. http://cn.bing.com/academic/profile?id=e5c29705f1dd1737b9455f15eb6d4c79&encoded=0&v=paper_preview&mkt=zh-cn
[3]	Kim JH, Bang YJ, Park BJ, et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study[J]. Jpn J Cancer Res, 2002, 93(5):471-477. doi: 10.1111/j.1349-7006.2002.tb01280.x
[4]	Hematology branch of Chinese medical doctor association, Hematology branch of Chinese medical association, Chinese working group of multiple myeloma. Chinese guideline of diagnosis and treatment for multiple myeloma (2013 version) [J]. Chin J Internal Medi, 2013, 52(9):791-795.
[5]	Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy[J]. Hepatology, 2006, 43(2):209-220. doi: 10.1002/hep.21051
[6]	Misra R, Jiobu K, Zhang J, et al. Racial disparities in hepatitis B infection in Ohio: screening and immunization are critical for early clinical management[J]. J Investig Med, 2013, 61(7):1121-1128. doi: 10.2310/JIM.0b013e3182a70f10
[7]	Park SC, Jeong SH, Kim J, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea[J]. J Med Virol, 2008, 80(6):960-966. doi: 10.1002/jmv.21168
[8]	Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma[J]. Ann Hematol, 2008, 87(6):475-480. doi: 10.1007/s00277-008-0469-9
[9]	Kang J, Cho JH, Suh CW, et al. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies[J]. Ann Hematol, 2011, 90(2):159-164. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a9832b73261e75fbea62eca470048033
[10]	Huang B, Li J, Zhou Z, et al. High prevalence of hepatitis B virus infection in multiple myeloma[J]. Leuk Lymphoma, 2012, 53(2):270-274. http://cn.bing.com/academic/profile?id=7962b3479e40cf09be94df26a8786e15&encoded=0&v=paper_preview&mkt=zh-cn
[11]	Ni F, Liu YY, Wu ZQ. Multiple myeloma associated with hepatitis B virus infection: a clinical observation[J]. Chin Clin Oncol, 2013, 18(9):804-807. http://cn.bing.com/academic/profile?id=f417f2b7547dd24c886fabab954e5a84&encoded=0&v=paper_preview&mkt=zh-cn
[12]	Teng CJ, Liu HT, Liu CY, et al. Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes[J]. Clinics (Sao Paulo), 2011, 66(12):2055-2061. doi: 10.1590/S1807-59322011001200010
[13]	Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol, 2009, 27(4):605-611. doi: 10.1200/JCO.2008.18.0182
[14]	Mandalà M, Fagiuoli S, Francisci D, et al. Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis [J]. Crit Rev Oncol Hematol, 2013, 87(1):12-27. https://pubmed.ncbi.nlm.nih.gov/23313021/
[15]	Bang SM, Kim SS, Park SH, et al. Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report[J]. Korean J Intern Med, 2004, 19(3):196-198. doi: 10.3904/kjim.2004.19.3.196
[16]	Bandi P, Garcia ML, Booth CJ, et al. Bortezomib inhibits hepatitis B virus replication in transgenic mice[J]. Antimicrob Agents Chemother, 2010, 54(2):749-756. doi: 10.1128/AAC.01101-09
[17]	Goldberg R, Smith E, Bell S, et al. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B[J]. Intern Med J, 2013, 43(7):835-836. doi: 10.1111/imj.12180
[18]	Tanaka H, Sakuma I, Hashimoto S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report[J]. J Clin Exp Hematop, 2012, 52(1):67-69. doi: 10.3960/jslrt.52.67
[19]	Beysel S, Yegn ZA, Yagci M. Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma[J]. Turk J Gastroenterol, 2010, 21(2):197-198. doi: 10.4318/tjg.2010.0087